Salvador Navarrete

Dr. Salvador Navarrete

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KHKarl Hage
Karl Hage
JBJuan S Barajas-Gamboa
Juan S Barajas-Gamboa
GRGustavo Romero-Velez
Gustavo Romero-Velez
MAMatthew Allemang
Matthew Allemang
SNSalvador Navarrete
Salvador Navarrete
Jerry DangJerry Dang
Jerry Dang
Introduction: The safety of conversional bariatric procedures after sleeve gastrectomy (SG) for weight recurrence (WR) or inadequate weight loss (IWL) is debated due to limited evidence. Conversion options include Roux-en-Y gastric bypass (RYGB), single anastomosis duodeno-ileal bypass (SADI), and biliopancreatic diversion with duodenal switch (BPD-DS). We aimed to compare serious complications and mortality rates between these procedures within 30 days. Methods: Using the 2020 and 2021 MBSAQIP databases, we identified patients who underwent a conversion from SG to RYGB, SADI, or BPD-DS. We performed a multivariable logistic regression to assess predictors of 30-day complications and mortality. Results: Among 7388 patients (77.6% RYGB, 8.7% SADI, 13.7% BPD-DS), those undergoing SADI and BPD-DS had higher preoperative body mass index. Conversion reasons included WR (63.0%) and IWL (37.0%). SADI and BPD-DS patients had longer operative times (p < 0.001) and higher leak rates (p = 0.001). Serious complications, reoperations, readmissions, and 30-day mortality were similar across groups. Conversion procedure type was not an independent predictor of complications. Conclusion: RYGB was the most performed conversional procedure after SG. The study indicated a similar safety profile for revisional RYGB, SADI, and BPD-DS, with comparable 30-day complications and mortality rates. However, SADI and BPD-DS patients had longer operative time and higher leak rates.


7 May 2025 in Obesity Surgery
Verified
Journal Article
Open access
PDF file
JBJuan Sebastian Barajas-Gamboa
Juan Sebastian Barajas-Gamboa
MKMohammed Sakib Ihsan Khan
Mohammed Sakib Ihsan Khan
KZKevin Zhan
Kevin Zhan
TSThomas H. Shin
Thomas H. Shin
VMValentin Mocanu
Valentin Mocanu
Jerry DangJerry Dang
Jerry Dang
Background: Conversional bariatric surgeries (CBS) are performed using laparoscopic and robotic techniques, but comprehensive data comparing these approaches remains scarce. Objective: To compare the indications and outcomes of laparoscopic versus robotic CBS. Methods: The MBSAQIP database was retrospectively analyzed from 2020 to 2022, comparing laparoscopic and robotic CBS. Primary outcomes were 30-day serious complications and mortality. Results: Of 72,189 CBS procedures, 75.4% were laparoscopic and 24.6% robotic. Mean age and BMI were similar between groups. The most common indications for both approaches were reflux, weight regain, and inadequate weight loss, with reflux being more prevalent in robotic CBS (38.3% vs 33.2%). Sleeve-to-bypass was the most common procedure in both groups (35.8% laparoscopic, 44.2% robotic). Robotic CBS had longer mean operative times (165.4 vs 121.7 min, p < 0.001) and slightly longer hospital stays (1.7 vs 1.6 days, p < 0.001). The rate of serious complications was slightly higher for robotic CBS, though not statistically significant (6.5% vs 6.1%, p = 0.08). Robotic CBS had higher rates of leak (0.9% vs 0.7%, p = 0.071), reoperation (2.8% vs 2.6%, p = 0.138), and readmission (6.7% vs 5.4%, p < 0.001). Mortality rates were similar (0.1% for both, p = 0.942). Conclusions: Both laparoscopic and robotic CBS show similar safety profiles with comparable mortality rates. However, robotic CBS was associated with longer operative times, slightly longer hospital stays, and higher readmission rates. These findings suggest that the choice between approaches should consider individual patient factors and institutional expertise.

Verified
Journal Article
Open access
PDF file
DEDoua Elamin
Doua Elamin
MWMélissa V. Wills
Mélissa V. Wills
JAJuan Aulestia
Juan Aulestia
VMValentin Mocanu
Valentin Mocanu
ASAndrew T Strong
Andrew T Strong
SNSalvador Navarrete
Salvador Navarrete
Background: Despite being one of the most performed bariatric procedures, there is no consensus regarding optimal limb lengths for Roux-en-Y gastric bypass (RYGB), which may impact weight loss and obesity-related comorbidity resolution. We hypothesize that a ratio-adjusted small bowel to Roux and BP limb lengths in RYGB results in superior outcomes. Objectives: This study aims to define total intestinal length (TIL) and the feasibility of its intraoperative measurement during RYGB. The findings will serve as a foundation for a subsequent randomized trial evaluating different limb length ratios and their effect on postoperative outcomes. Setting: This was a single-center prospective cohort study conducted at Cleveland Clinic Foundation-Main Campus, a tertiary referral center in the United States. Methods: Between January and June 2023, 25 patients with BMI > 40 undergoing RYGB were enrolled. Total small bowel length was measured intraoperatively, and feasibility of measurement was assessed. Patient outcomes, including total weight loss, 30-day complications, and comorbidities at 1 year were captured. Results: Mean preoperative BMI was 47.6 ± 8.0 kg/m2. Mean total small bowel length was 592 ± 93.3 cm, with a mean biliopancreatic (BP) limb length of 109 ± 29 cm (18.86% ± 5.84 of total length) and Roux limb length of 103 ± 15 cm (17.71% ± 3.06 of total length). Measurement added an average of 11.5 min to operative time. Measurement feasibility was rated as “moderate” or easier in 80% of cases. One-year postoperative outcomes included a mean total weight loss of 31% and significant reductions in antihypertensive and anti-diabetic medication use. Conclusions: Total small bowel length measurement during RYGB is safe and feasible. High variability in bowel length was observed, with no significant correlation to demographic factors. Establishing individualized limb length ratios may improve weight loss outcomes and comorbidity resolution. Further studies are warranted to evaluate the impact of tailored limb length strategies.

20 March 2026 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
VMValentin Mocanu
Valentin Mocanu
MWMélissa V. Wills
Mélissa V. Wills
SNSalvador Navarrete
Salvador Navarrete
PKPattharasai Kachornvitaya
Pattharasai Kachornvitaya
XZXinlei Zhu
Xinlei Zhu
Jerry DangJerry Dang
Jerry Dang

25 September 2025 in Obesity Surgery
Verified
Journal Article
Open access
PDF file
JBJuan Sebastian Barajas-Gamboa
Juan Sebastian Barajas-Gamboa
KKKayanne Khoury
Kayanne Khoury
VMValentin Mocanu
Valentin Mocanu
MWMélissa V. Wills
Mélissa V. Wills
TSThomas H Shin
Thomas H Shin
Jerry DangJerry Dang
Jerry Dang
Introduction: Concomitant liver biopsy during bariatric surgery has gained interest for diagnostic and research purposes, particularly in studying obesity-related liver disease. However, comprehensive data on safety remains limited using recent national databases. Methods: A retrospective analysis of the MBSAQIP database from 2020 to 2022 was conducted. Patients undergoing primary Roux-en-Y gastric bypass or sleeve gastrectomy with or without concomitant liver biopsy were included. Primary outcomes were 30-day major complications (Clavien-Dindo grade III and IV) and mortality. Separate multivariable analyses were performed for bleeding-related complications including postoperative bleeding, transfusion requirements, and reoperation. Multivariable logistic regression analysis determined if concomitant liver biopsy independently predicted adverse outcomes. Results: Of 511,981 patients, 30,819 (6.02%) underwent concomitant liver biopsy. Biopsy patients had higher rates of diabetes (28.25% vs 22.65%, p < 0.001) and hyperlipidemia (25.20% vs 22.14%, p < 0.001). Mean operative time was longer in the biopsy group (96.10 vs 83.59 min, p < 0.001). Unadjusted analysis showed higher rates of major complications (Clavien-Dindo grade III and IV) (3.15% vs 2.70%, p < 0.001) and 30-day readmission (3.32% vs 2.86%, p < 0.001) in the biopsy group. However, on multivariable analysis, concomitant liver biopsy was not independently predictive of major complications (OR 0.91, 95%CI 0.79–1.04, p = 0.164) or 30-day readmission (OR 1.06, 95%CI 0.94–1.21, p = 0.344). Separate multivariable analyses for bleeding-related complications revealed that concomitant liver biopsy was independently associated with increased postoperative bleeding (OR 1.203, 95%CI 1.018–1.422, p = 0.030) and transfusion requirements (OR 1.171, 95%CI 1.028–1.334, p = 0.018), but not with reoperation (OR 1.016, 95%CI 0.908–1.138, p = 0.783). Conclusion: After adjusting for patient factors, concomitant liver biopsy during bariatric surgery does not independently increase the risk of major complications (Clavien-Dindo grade III and IV), readmission, or mortality. However, it is associated with increased bleeding and transfusion complications. These findings support that liver biopsy can be performed during bariatric surgery, though clinicians should be prepared for increased bleeding-related risks and blood product utilization.